| gap-pubmed-20260410- | How do the four CR pathways (IGF-1/insulin, sirtuin, AMPK, TOR) interact to gene | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Does diminished neurogenesis contribute to AD onset/progression or merely correl | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurogenesis |
| gap-pubmed-20260410- | What mechanisms explain how inflammation links MDD and AD despite different gene | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Which specific subtypes of early-life MDD confer independent high risk for later | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How do temporal dynamics of RBP dysfunction differ between ALS, FTD, and AD dise | resolved | 0.70 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Which specific chaperone systems selectively handle RNA binding protein quality | open | 0.75 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | What are the optimal delivery mechanisms for antisense oligonucleotides targetin | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | drug-delivery |
| gap-debate-20260410- | Do chronic stress granule inhibition strategies impair normal cellular stress re | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How do individual circadian rhythm variations affect the therapeutic window for | open | 0.68 | 0.00 | 2026-04-10 | 0 | | chronobiology |
| gap-debate-20260410- | What biomarkers can reliably measure real-time glymphatic function to guide slee | open | 0.75 | 0.00 | 2026-04-10 | 0 | | biomarker-development |
| gap-debate-20260410- | Does glymphatic enhancement from sleep interventions directly cause tau clearanc | resolved | 0.78 | 0.00 | 2026-04-10 | 0 | | neuroscience |
| gap-debate-20260410- | Can orexin antagonism timing be precisely controlled to enhance glymphatic tau c | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Can qualitative research methods be systematically integrated into neurodegenera | open | 0.68 | 0.00 | 2026-04-10 | 0 | | clinical-research-methodology |
| gap-debate-20260410- | What standardized protocols are needed to bridge methodological tools with neuro | open | 0.75 | 0.00 | 2026-04-10 | 0 | | translational-research |
| gap-debate-20260410- | How can methodological rigor be maintained when literature-hypothesis mismatches | open | 0.82 | 0.00 | 2026-04-10 | 0 | | research-methodology |
| gap-debate-20260410- | Can TYROBP stabilization maintain TREM2 signaling independently of surface recep | open | 0.75 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | How do APOE4 genotype interactions with TREM2 modulators affect therapeutic safe | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | pharmacogenomics |
| gap-debate-20260410- | What is the optimal timing window for TREM2-targeted interventions across Alzhei | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | clinical-neuroscience |
| gap-debate-20260410- | Does SYK activation provide neuroprotection or exacerbate neuroinflammation in e | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Can substrate reduction therapy prevent neurodegeneration in asymptomatic GBA ca | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Do compensatory sphingolipid pathways generate new toxic intermediates during GC | open | 0.75 | 0.00 | 2026-04-10 | 0 | | biochemistry |
| gap-debate-20260410- | Can TFEB chronic activation cause lysosomal storage dysfunction that counteracts | open | 0.80 | 0.00 | 2026-04-10 | 0 | | cell-biology |
| gap-debate-20260410- | What is the therapeutic window between GCS inhibition efficacy and systemic toxi | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the critical unanswered questions regarding therapeutic intervention in | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do genetic variants in mitochondrial calcium transport proteins contribute t | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific mechanisms by which disrupted mitochondrial calcium cyclin | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the optimal integration strategy for molecular and histological | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do molecular markers mechanistically drive glioma pathogenesis beyond their | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do wild-type IDHs regulate normal brain physiology and what happens when thi | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms explain how wild-type IDH downregulation specifically contribute | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What is the optimal timing window for gut barrier interventions to prevent AD pa | open | 0.75 | 0.00 | 2026-04-10 | 0 | | clinical-translation |
| gap-debate-20260410- | Which specific microbiome dysbiotic signatures predict optimal probiotic strain | open | 0.80 | 0.00 | 2026-04-10 | 0 | | precision-medicine |
| gap-debate-20260410- | How can microglial activation be selectively enhanced for Aβ clearance while sup | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-debate-20260410- | What brain concentrations of SCFAs are achieved via oral probiotics and are they | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | pharmacokinetics |
| gap-debate-20260410- | How should research workflows handle fundamental input-output incompatibilities? | open | 0.68 | 0.00 | 2026-04-10 | 0 | | research-methodology |
| gap-debate-20260410- | What quality control mechanisms ensure literature relevance in systematic resear | open | 0.75 | 0.00 | 2026-04-10 | 0 | | research-methodology |
| gap-debate-20260410- | How can AI systems detect and prevent literature-task mismatches in automated re | open | 0.82 | 0.00 | 2026-04-10 | 0 | | research-methodology |
| gap-debate-20260410- | Can automated systems detect domain-literature mismatches in multi-expert resear | open | 0.65 | 0.00 | 2026-04-10 | 0 | | research-informatics |
| gap-debate-20260410- | What standardized protocols exist for validating hypothesis-literature alignment | open | 0.70 | 0.00 | 2026-04-10 | 0 | | research-methodology |
| gap-debate-20260410- | How can research methodology frameworks be systematically matched to appropriate | open | 0.75 | 0.00 | 2026-04-10 | 0 | | research-methodology |
| gap-debate-20260410- | How do circadian disruptions specifically affect SPM synthesis enzyme expression | open | 0.70 | 0.00 | 2026-04-10 | 0 | | chronobiology |
| gap-debate-20260410- | Can astrocyte-microglial SPM transfer occur via gap junctions or exosomes in neu | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurobiology |
| gap-debate-20260410- | What are the temporal dynamics of SPM synthesis gene silencing during neurodegen | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Do SPM receptors undergo desensitization with chronic agonist treatment, prevent | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | pharmacology |
| gap-debate-20260410- | Does p21 protein degradation selectively eliminate senescent cells without disru | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | How can senolytics achieve brain-specific delivery while avoiding off-target eff | open | 0.85 | 0.00 | 2026-04-10 | 0 | | drug-delivery |
| gap-debate-20260410- | What distinguishes truly senescent brain cells from merely dysfunctional reactiv | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | cellular-senescence |
| gap-debate-20260410- | Do senescent brain cells exhibit circadian-dependent vulnerability to senolytic | open | 0.75 | 0.00 | 2026-04-10 | 0 | | chronobiology |
| gap-pubmed-20260410- | What determines the specific accumulation of neutrophil membrane-coated nanopart | open | 0.78 | 0.00 | 2026-04-10 | 0 | | nanomedicine |
| gap-pubmed-20260410- | How does cerium doping specifically enhance Prussian blue's anti-pyroptotic acti | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |